Thomas Stephan
Stock Analyst at Stifel Nicolaus
Total Price Targets
11
Stocks Covered
5
Sectors
Healthcare
Most Recent
Mar 9, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Thomas Stephan
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| RXST | RxSight, Inc. | $9.00 | $7.33 | +22.7% | 3 | Mar 9, 2026 |
| GMED | Globus Medical, Inc. | $64.00 | $91.62 | -30.1% | 1 | Oct 28, 2025 |
| GKOS | Glaukos Corporation | $115.00 | $142.00 | -19.0% | 5 | Oct 27, 2025 |
| ALC | Alcon Inc. | $85.00 | $74.45 | +14.2% | 1 | Sep 29, 2025 |
| STAA | STAAR Surgical Company | $28.00 | $26.99 | +3.7% | 1 | Aug 7, 2025 |
Recent Activity
- Mar 9, 2026— Set$9.00price target onRXST(RxSight, Inc.)
- Oct 28, 2025— Set$64.00price target onGMED(Globus Medical, Inc.)
- Oct 27, 2025— Set$115.00price target onGKOS(Glaukos Corporation)
- Sep 29, 2025— Set$85.00price target onALC(Alcon Inc.)
- Aug 7, 2025— Set$28.00price target onSTAA(STAAR Surgical Company)
- Dec 31, 2024— Set$175.00price target onGKOS(Glaukos Corporation)
- Dec 2, 2024— Set$153.00price target onGKOS(Glaukos Corporation)
- Sep 3, 2024— Set$145.00price target onGKOS(Glaukos Corporation)
- Aug 6, 2024— Set$65.00price target onRXST(RxSight, Inc.)
- Jun 5, 2024— Set$130.00price target onGKOS(Glaukos Corporation)
- May 6, 2024— Set$68.00price target onRXST(RxSight, Inc.)
Frequently Asked Questions
Who is Thomas Stephan?
Thomas Stephan is a stock analyst at Stifel Nicolaus covering 5 stocks primarily in Healthcare. They have issued 11 price targets since May 6, 2024.
What stocks does Thomas Stephan cover?
Thomas Stephan currently covers 5 stocks, including GKOS, RXST, GMED, ALC, STAA.
What is Thomas Stephan's latest price target?
Thomas Stephan's most recent price target was $9.00 on RXST (RxSight, Inc.), set on Mar 9, 2026.
What is Thomas Stephan's highest price target?
Thomas Stephan's highest issued price target is $175.00 on GKOS, set on Dec 31, 2024.
More Analysts at Stifel Nicolaus
Coverage based on publicly published price targets. Not investment advice.